Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McKESSON MULTI-SOURCE GENERIC LINE WILL INCLUDE LIQUIDS

Executive Summary

McKESSON MULTI-SOURCE GENERIC LINE WILL INCLUDE LIQUIDS beginning in February 1989. Barre-National will be adding 100 oral liquid products to the Multi-Source line. The liquids will supplement McKesson's Multi-Source program, which was launched a year ago to provide competitively priced generic lines to independent pharmacists. In addition, McKesson has just begun to offer Rx generic creams and ointment products through the Multi-Source program. NMC is McKesson's supplier of cream and lotion dosage forms. The McKesson Multi-Source Program has been providing an oral generic prescription line of 500 SKUs through five suppliers: United Research Labs, Mylan, Par, Squibb and NMC. A McKesson spokesman estimated that the program supplies 80% of independent pharmacists' generic needs, stepped up to 85-90% with the addition of the Barre-National line. Commenting on the program's success at a meeting for securities analysts in New York City Nov. 10, Exec VP-Operations Rex Malson listed the Multi-Source program among the wholesaler's value-added services for independent pharmacy customers. "These drugs sell for substantially less, but carry higher gross margins for us as well as our customers," Malson noted.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS014646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel